Skip to main content

Table 1 Characteristics of all patients between MSD and AD

From: Alternative donor peripheral blood stem cell transplantation for the treatment of high-risk refractory and/or relapsed childhood acute leukemia: a randomized trial

VariablesMSD(n = 42)AD(n = 69)χ2P value
Gender (n, %)0.1720.678
 Male27 (64.3)47 (68.1)
 Female15 (35.7)22 (31.9)
Primary disease (n, %)0.0160.899
 AML22 (52.4)37 (53.6)
 ALL20 (47.6)32 (46.4)
Disease status at HSCT (n, %)1.8730.392
 First CR19 (45.2)39 (56.5)
 Second and other CR16 (38.1)18 (26.1)
 Relapse7 (16.7)12 (17.4)
Disease status at HSCT (n, %)1.3320.248
 First CR19 (45.2)39 (56.5)
 Other23 (54.8)30 (43.5)
Extramedullary infiltration (n, %)2.5380.111
 Yes8 (19.0)6 (8.7)
 No34 (81.0)63 (91.3)
Conditioning regimen (n, %)0.0820.775
 Bu/Cy-based30 (71.4)51 (73.9)
 TBI/Cy-based12 (28.6)18 (26.1)
Gender of donor-recipient (n, %)5.6690.017
 Identical19 (45.2)47 (68.1)
 Different23 (54.8)22 (31.9)
Donor-recipient ABO compatibility (n, %)0.0140.907
 Compatible19 (45.2)32 (46.4)
 Incompatible23 (54.8)37 (53.6)
Abnormal markersNANA
 t(9;22)8 (19.0)13 (18.8)
 MLL/AF41 (2.4)3 (4.3)
 FLT3/ITD2 (4.8)1 (1.4)
MRD0.0140.906
 Yes12 (28.6)19 (27.5)
 No30 (71.4)50 (72.5)
MNC (× 108/kg)11.74 (3.98–31.03)14.57 (3.57–47.11)NANA
CD34 + cells(× 106/kg)5.84 (3.43–23.30)8.33 (3.07–35.7)NANA
Time for implantation of neutrophils (d)12 (9–19)13 (10–26)NANA
Time for implantation of PLT(d)13 (8–30)13 (9–26)NANA
  1. MSD matched sibling donor, AD alternative donor, AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, HSCT hematopoietic stem cell transplantation, CR complete remission, BU busulfan, TBI total body irradiation, Cy cyclophosphamide, MRD minimal residual disease MNC mononuclear cells, PLT platelet, NA not applicable